CING Live signaler | Maksimer profitt med Getagraph.com

SELG 112951 min ago

@ $1.240

Utstedt: 13 feb 2024 @ 15:47

Avkastning: -16.13%

Forrige signal: feb 9 - 16:37

Forrige signal: Kjøp

Avkastning: 7.63 %

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder...

Stats
Dagens volum	61 077.00
Gjennomsnittsvolum	272 462
Markedsverdi	4.14M
EPS	$-5.94 ( 2024-04-05 )
Neste inntjeningsdato	( $-2.20 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.00600 (0.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Werth Peter J.	Buy	694 096	Common Stock
2024-04-11	Werth Peter J.	Buy	341 912	Common Stock
2024-04-11	Werth Peter J.	Sell	694 096	Pre-Funded Warrant (right to buy)
2024-04-11	Werth Peter J.	Sell	341 912	Pre-Funded Warrant (right to buy)
2024-03-29	Silva Raul R.	Buy	1 000	Stock Option (right to Buy)

INSIDER POWER
77.31
Last 96 transactions
Buy: 11 671 641 \| Sell: 1 062 040

Cingulate Inc. Korrelasjon

10 Mest positive korrelasjoner
ADXN	0.805

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cingulate Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-582 918 (0.00 %)
EPS:	$-26.00

FY	2023
Omsetning:	$0
Bruttogevinst:	$-582 918 (0.00 %)
EPS:	$-26.00

FY	2022
Omsetning:	$0
Bruttogevinst:	$-621 993 (0.00 %)
EPS:	$-31.57

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.831

Financial Reports:

No articles found.

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.